Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy (PantoCIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03948477
Recruitment Status : Not yet recruiting
First Posted : May 14, 2019
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
Dr Richard Isaacs, University of Auckland, New Zealand

Brief Summary:

This study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer.

Delayed nausea, and occasionally vomiting, can occur after breast cancer chemotherapy, affecting quality of life. A potential cause of these delayed side effects is that the chemotherapy may cause stomach irritation. Pantoprazole is commonly used to treat stomach irritation by reducing stomach acid, which may in turn improve nausea and/or vomiting.

Patients undergoing breast cancer chemotherapy before or after primary surgery will be invited to participate in the study. They will be asked how much nausea or vomiting they have with and without Pantoprazole from Day 2 until 5 after they receive chemotherapy. All participants will still receive all of the usual anti-sickness medications, which are very effective in preventing sickness in the first 24 hours after treatment, but not for delayed symptoms.

Information from the study may lead to a change in practice with patients using Pantoprazole to reduce the risks of delayed nausea and vomiting.


Condition or disease Intervention/treatment Phase
Oncology Breast Cancer Chemotherapy-induced Nausea and Vomiting Drug: Pantoprazole 40mg Drug: Placebo Phase 2

Detailed Description:
Breast Cancer is the most common cancer type in women in New Zealand and has the second highest mortality (Ministry of Health NZ) Many women with early breast cancer still receive chemotherapy, before or after surgery and delayed nausea is a particular challenge. Ensuring tolerable therapy is critical to improving outcomes, by enabling patients to complete optimal anti-cancer therapy and to improve quality of life during therapy. Despite recent advances in antiemetic regimens, recent trials showed that rates of delayed Chemotherapy-Induced Nausea and Vomiting (CINV) are is in excess of 50%, with significant impacts on quality of life during treatment. This suggests that different mechanisms than those targeted by centrally acting anti-emetics account for such symptoms. There is strong evidence that chemotherapy regimens can result in gastrointestinal mucosal injury and dyspepsia. A number of studies have shown chemotherapy-induced dyspepsia can be relieved by a proton pump inhibitor, but none have reported their use as prophylaxis for delayed CINV, which may be a linked symptom. Proton pump inhibitors are widely used in the treatment of non-malignant dyspeptic conditions and are the most potent medications at reducing gastric acid secretions. They are considered safe in short-term use and are commonly used in clinical practice in cancer patients as well as the wider population. The pharmacokinetics Pantoprazole make it the ideal PPI for this study. The experience of New Zealand Medical Oncologists is that delayed nausea is often completely resolved by the delayed use of a PPI when symptoms occur. In this study we hope to see a 30% difference in the rates of delayed nausea by using a drug which is readily available and of very low cost. This will be the first time it has been used as preventive therapy in this setting. If this benefit occurs, it would significantly improve the treatment journey and may improve compliance to anti-cancer therapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Double-blinded, randomised, crossover trial, phase II, stratified by the chemotherapy regimen
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-blinded
Primary Purpose: Prevention
Official Title: Phase II, Randomised, Double-blinded, Placebo Controlled, Crossover Trial to Assess Pantoprazole's Effectiveness as Prophylaxis Against Delayed CINV in Patients Receiving Adjuvant or Neoadjuvant Breast Cancer Chemotherapy
Estimated Study Start Date : May 14, 2019
Estimated Primary Completion Date : June 14, 2021
Estimated Study Completion Date : July 15, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Pantoprazole/Placebo
Participants will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 1 then they will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 2
Drug: Pantoprazole 40mg
Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
Other Name: Apo-Pantoprazole

Drug: Placebo
Matched placebo

Placebo/Pantoprazole
Participants will take one capsule of matched Placebo daily for 5 days at the beginning of cycle 1 then they will take one 40 mg capsule of Pantoprazole daily for 5 days at the beginning of cycle 2
Drug: Pantoprazole 40mg
Proton pump inhibitor, drug action is to irreversibly block the hydrogen-potassium adenosine triphosphatase enzyme system (the 'proton pump') of the gastric parietal cell. This reduces basal and stimulated gastric acid secretion therefore raising gastric pH.
Other Name: Apo-Pantoprazole

Drug: Placebo
Matched placebo




Primary Outcome Measures :
  1. Reduce the incidence of delayed CINV in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy [ Time Frame: Measured on day 5, after chemotherapy ]
    To determine whether Pantoprazole can reduce the incidence of delayed CINV in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy (as measured on day 5 using the MASCC Antiemesis Tool (MAT) to assess nausea over days 2-5 of each chemotherapy cycle) as compared to placebo. Specifically, the primary endpoint will be the complete absence of both nausea and vomiting during days 2-5.


Secondary Outcome Measures :
  1. Nausea MAT scores [ Time Frame: Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days) ]
    Whether Pantoprazole improves nausea MAT scores over days 2-5

  2. Vomiting MAT scores [ Time Frame: Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days) ]
    Whether Pantoprazole reduces the number of episodes of vomiting (MAT) over days 2-5

  3. Heartburn improvement [ Time Frame: Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days) ]
    Whether Pantoprazole improves heartburn score (measured using the FSSG for reflux and/or dyspepsia) as self-reported on day 5 regarding days 2-5.

  4. Heartburn and Nausea scores [ Time Frame: Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days), using a regression model, with allowance for a possible non-linear relationship. ]
    Whether FSSG scores (heartburn) are associated with the MAT nausea scores reported by the patient over days 2-5.

  5. Use of breakthrough medications [ Time Frame: Days 2-5 following chemotherapy for cycle 1 and 2 (each cycle is either 14 or 21 days) ]
    Whether Pantoprazole lowers the requirement for breakthrough medications (as self-recorded by the patients on days 2-5).

  6. Patient preference [ Time Frame: end of chemotherapy cycle 2 (cycle 2 is either 14 or 21 days) ]
    Whether Pantoprazole is preferred by patients over Placebo (by using a patient preference survey at the end of cycle 2).

  7. Adverse events [ Time Frame: From date of consent to 28 days after the last study treatment ]
    To assess whether adverse events (including hypomagnesemia, diarrhoea, abdominal pain and headache as defined by CT CAE version 4.03) are more common on Pantoprazole than on Placebo.


Other Outcome Measures:
  1. Effect of chemotherapy regimen impacts use of Pantoprazole in terms of delayed CINV [ Time Frame: Measured on day 5, after chemotherapy ]
    Whether the chosen chemotherapy regimen (FEC vs AC vs TC) has an impact on the benefits of Pantoprazole in terms of delayed CINV, (as measured on day 5 using the MASCC Antiemesis Tool (MAT) to assess nausea over days 2-5 of each chemotherapy cycle) as compared to placebo.

  2. Cycle effect [ Time Frame: Cycle 1 to end of cycle 2 (each cycle is either 14 or 21 days) ]
    To determine whether there is a cycle effect with respect to the incidence of delayed CINV as measured with the MAT (as measured on day 5 using the MASCC Antiemesis Tool (MAT) to assess nausea over days 2-5 of each chemotherapy cycle).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men or women who are being considered for adjuvant or neoadjuvant chemotherapy with either FEC or AC or TC chemotherapy and have been deemed by their treating Oncologist as being fit for treatment. The scheduled length of each chemotherapy cycle must be 14-21 days.
  2. Age ≥18 years.
  3. Willing to comply with all study requirements, including treatment (being able to swallow tablets), timing and nature of required assessments.
  4. All patients must be able to speak and read in English to ensure consent is informed and documentation of patient-reported outcome measures can be adhered to.
  5. Signed, written informed consent.

    -

Exclusion Criteria:

  1. Patients who are receiving therapy to reduce gastric acid (including proton pump Inhibitors (e.g. Omeprazole, Pantoprazole, Lansoprazole, Esomeprazole or Histamine type-2 receptor antagonists e.g. Ranitidine)) at the time of enrolment will be excluded from the trial.
  2. Patients with pre-existing hypomagnesemia as defined by the reference range at the investigating sites laboratory.
  3. Patients with a history of cardiac arrhythmias including atrial fibrillation or paroxysmal tachycardias.
  4. Patients with known metastatic disease.
  5. The presence of any serious medical or psychiatric conditions, which might limit the ability of the patient to comply with follow up.
  6. The presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule, including alcohol dependence or drug abuse.
  7. Pregnancy, lactation or inadequate contraception. Women must be postmenopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03948477


Contacts
Layout table for location contacts
Contact: Louise Clement, MA +64 (0)99234626 louise.clement@auckland.ac.nz
Contact: Sarah Benge, PhD +64 (0)9 923 3585 s.benge@auckland.ac.nz

Sponsors and Collaborators
University of Auckland, New Zealand
Investigators
Layout table for investigator information
Principal Investigator: Ricard Isaacs, MBChB FRACP Midcentral Regional Cancer Centre Services
Principal Investigator: Navin Wewala, MBChB FRACP Midcentral Regional Cancer Centre Services

Additional Information:
Layout table for additonal information
Responsible Party: Dr Richard Isaacs, Medical Oncologist, University of Auckland, New Zealand
ClinicalTrials.gov Identifier: NCT03948477     History of Changes
Other Study ID Numbers: CTNZ-2017-17
First Posted: May 14, 2019    Key Record Dates
Last Update Posted: May 14, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Vomiting
Skin Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Pantoprazole
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action